戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 cyclosporin A, ondansetron, domperidone, and loperamide.
2 ant diarrhea did not occur with prophylactic loperamide.
3 istered twice daily by mouth with concurrent loperamide.
4 grade symptoms can be managed with continued loperamide.
5 ted at 24 mg/m(2), despite aggressive use of loperamide.
6 try of the PET radiotracer (11)C-N-desmethyl-loperamide ((11)C-dLop).
7 s metabolism to [N-methyl-(11)C] N-desmethyl-loperamide ([(11)C]dLop; [(11)C]3) precludes quantificat
8 it is rapidly metabolized to 11C-N-desmethyl-loperamide (11C-dLop), which is also a substrate for P-g
9 trials), psychotropic agents (7 trials), and loperamide (4 trials).
10  derived from the MOR agonists TRV130 (3) or loperamide (6).
11 at Cereport was able to increase delivery of loperamide across the BBB, allowing it to gain access to
12 o diminish by 120 min following Cereport and loperamide administration.
13                                              Loperamide alone did not produce analgesia.
14                 Aggressive administration of loperamide also reduced the incidence of grade 4 diarrhe
15                                              Loperamide, an opiate receptor agonist, does not cross t
16 tinence, clinicians could consider combining loperamide, anal manometry-assisted biofeedback, and a s
17 ivalent to an educational pamphlet, and that loperamide and biofeedback are equivalent to oral placeb
18 ported by two (2%) of 86 participants in the loperamide and biofeedback group and two (2%) of 88 in t
19 tion (-0.7 points, -2.6 to 1.2, p=0.47), and loperamide and biofeedback versus placebo and biofeedbac
20 ict adherence to an antidiarrheal regimen of loperamide and diphenyldramine.
21 brain barrier, P-gp blocks the entry of both loperamide and its metabolite, N-desmethyl-loperamide (N
22                                     Both 11C-loperamide and its putative radiometabolite 11C-dLop are
23                    The nonprescription drugs loperamide and mitragynine are associated with dispropor
24              The brain concentrations of 11C-loperamide and the putative 11C-dLop were about 16-fold
25 ing anxiety, such as estradiol, pirenperone, loperamide, and disopyramide.
26 ry, repeated--assessment, appropriate use of loperamide, and knowledge of fluid resuscitation require
27 del basic drugs (nortriptyline, haloperidol, loperamide, and papaverine) in physiological solutions,
28               Monkeys were injected with 11C-loperamide, and PET brain images were acquired for 120 m
29       For three P-gp substrates (amprenavir, loperamide, and quinidine), we have successfully fitted
30                             We evaluated 11C-loperamide as a PET radiotracer to measure P-gp function
31                                              Loperamide at 10-30 microM has no effect on intracellula
32 se of irinotecan 125 mg/m2 and by initiating loperamide at the earliest signs of diarrhea.
33                              It appears that loperamide augments influx of calcium through activated
34 tron microscopy maps of MOR with naloxone or loperamide, capturing several intermediate conformations
35                Only in astrocytoma cells did loperamide cause an elevation in intracellular calcium i
36                                              Loperamide caused augmentation of intracellular calcium
37          Patients in the TAI group used less loperamide compared to the control group (36% vs. 79%).
38              Antidiarrheal agents (including loperamide, diphenoxylate, and difenoxin) and the tricyc
39           The radiotracer [(11)C]N-desmethyl-loperamide (dLop) images the in vivo function of P-glyco
40 d selective P-gp substrate (11)C-N-desmethyl-loperamide (dLop) while avoiding side effects associated
41 of anorectal manometry-assisted biofeedback, loperamide, education, and oral placebo.
42  and trifluoperazine) that in the absence of loperamide effectively blocked SOC channels.
43 s, (3)H-verapamil (threefold increase), (3)H-loperamide (fivefold increase), and (3)H-paclitaxel (fiv
44 ually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms.
45 ed the intestinal background volume, whereas loperamide had a significant but moderate effect.
46                                       [(11)C]Loperamide has been proposed for imaging P-glycoprotein
47                                              Loperamide has no effect when levels of intracellular ca
48   Consequently, the over-the-counter opioids loperamide (Imodium A-D) and mitragynine, the herbal ing
49 rged, among them that methadone, emetine and loperamide (Imodium) may antagonize muscarinic M3, alpha
50 ntation of intracellular calcium elicited by loperamide in cultured cells was dependent on extracellu
51              11C-dLop may be superior to 11C-loperamide in measuring P-gp function at the blood-brain
52 ent choices for diarrhea management included loperamide in the majority of patients.
53  and partly with the CES2-specific inhibitor loperamide, indicating that carboxylesterase Ces2a, whic
54 netic studies with the Mdr1a P-gp substrates loperamide, indinavir, and talinolol indicated that Mdr1
55 kg fully normalized stool water content in a loperamide-induced mouse model of constipation.
56                                          11C-Loperamide is an avid substrate for P-glycoprotein (P-gp
57                                              Loperamide is effective for diarrhea.
58 nd evidence against the null hypotheses that loperamide is equivalent to placebo, that anal exercises
59 e shown that (11)C-dLop, compared with (11)C-loperamide, is an especially promising radiotracer becau
60  (1650 mg; 107 persons), in combination with loperamide (labeled dosing).
61 ontent and intestinal ink propulsion rate in loperamide (Lope)-induced STC rats.
62                               Treatment with Loperamide, low-fiber diets, and bile salt- binding ther
63 10 muL of whole blood containing citalopram, loperamide, methadone, and sertraline as model substance
64 1.2, 5.5, 2.0, and 5.3 ng/mL for citalopram, loperamide, methadone, and sertraline, respectively.
65     Reports involving nonprescription drugs (loperamide, mitragynine) and diphenoxylate/atropine (Lom
66 lation by measuring defecatory behavior in a loperamide model of constipation in rats.
67 h loperamide and its metabolite, N-desmethyl-loperamide (N-dLop), and thereby prevents central opiate
68 , the apparent positive modulatory effect of loperamide on SOC channels occurs when these channels ha
69        Participants received 2 mg per day of loperamide or oral placebo with the option of dose escal
70 0 g in those with constipation, those taking loperamide or other opioids for diarrhea, and those taki
71    Patients were administered either 4 mg of loperamide orally before (18)F-4FMFES tracer injection o
72 quivalent to oral placebo and biofeedback or loperamide plus an educational pamphlet.
73 eedback, loperamide plus education only, and loperamide plus anorectal manometry-assisted biofeedback
74 ion (n=88), and the combined intervention of loperamide plus biofeedback (n=86).
75 -1.9 points, -4.1 to 0.3, p=0.092) or versus loperamide plus education (-1.1 points, -3.4 to 1.1, p=0
76 ion (n=42), placebo plus biofeedback (n=84), loperamide plus education (n=88), and the combined inter
77  biofeedback group and two (2%) of 88 in the loperamide plus education group.
78 us anorectal manometry-assisted biofeedback, loperamide plus education only, and loperamide plus anor
79 ice with NG-nitro-L-arginine methyl ester or loperamide prevented both the increased motility and the
80 inistration of a combination of Cereport and loperamide produced a significant analgesic effect (2-fo
81 xone stalls MOR in a 'latent' state, whereas loperamide promotes an 'engaged' state, which is structu
82 rring in 21% of patients taking prespecified loperamide prophylaxis and 28% of those without prophyla
83                                              Loperamide reduced GI motility of irinotecan treated mic
84 ic use, consistent with clinical findings of loperamide refractory diarrhea in patients.
85 ndividual patient tolerance and an intensive loperamide regimen for the management of diarrhea.
86                                              Loperamide remains the standard therapy for uncomplicate
87                                              Loperamide seems to reduce diarrhea but does not relieve
88  an antidiarrheal regimen of diphenhydramine/loperamide significantly reduced the incidence of diarrh
89 the uptake of the known P-gp substrate (11)C-loperamide, suggesting that the effects of disulfiram in
90 y of the peripherally acting opiate agonist, loperamide, to the brain, as evidenced by induction of a
91 g agents: eluxadoline, rifaximin, alosetron, loperamide, tricyclic antidepressants, selective seroton
92  24 weeks, there were no differences between loperamide versus placebo (model estimated score change
93  rifaximin, alosetron, (moderate certainty), loperamide (very low certainty), tricyclic antidepressan
94                                              Loperamide was also significantly associated with arrhyt
95 ithromycin, levofloxacin, and rifaximin with loperamide were comparable for treatment of acute watery
96  analgesic effects of combining Cereport and loperamide were completely blocked when animals were pre